Investor Relations Corporate Overview Stock Information Financial Tearsheet Press Releases Events & Presentations SEC Filings Corporate Governance Management Team Board of Directors Analyst Coverage IR Contacts Email Alerts Corporate Overview Petros is a Men’s Health pharmaceutical company that aims to develop complementary therapeutics designed for a man’s journey, often, we believe, centered around the ones he loves and lives for. Petros aims to revolutionize the art and science behind the way men approach their health emphasizing the critical elements of medication adherence, tolerability, preservation of organic function and the restoration of vitality. Each element approached within an integrated and interdependent perspective, targeting tangible enhancements to their health outcomes. Ultimately, Petros seeks to establish new foundations to Men’s Health that center around the whole of a man’s life and function. LATEST NEWS INVESTOR PRESENTATION About Learn Science Investors Terms of Use Privacy Policy California Compliance Careers © 2021 Metuchen. All Rights Reserved.

About Us Petros is actively researching new formulations across several serious men’s health conditions, and will continue to build up its broader portfolio and pipeline. The Petros leadership team hosts extensive experience in the bio-pharmaceutical industry with experience in successful clinical development programs, regulatory approvals, commercial launches and enduring market-leading innovations; many of which were in the Men’s Health marketplace. This executive team will also solidify the long-term portfolio aspirations of the organization, with late-stage innovative therapies intended to treat underserved, misunderstood and largely unaddressed Men’s Health conditions. Petros Pharmaceuticals was founded upon its first, and currently commercialized Men’s Health therapeutic, a distinct molecule in erectile dysfunction, with an aim to continue awareness, education and therapeutic value to the Men’s sexual dysfunction landscape. In a continued effort to expand its portfolio into other underserved segments, Petros Pharmaceuticals has recently executed a definitive global exclusive licensing agreement for a novel and patented topical formulation candidate for the treatment of Peyronie’s disease (PD), which is currently going through early clinical testing. If approved, it would become the first and only clinically proven topical, non-invasive treatment for acute PD, a landmark achievement in men’s health. About Learn Science Investors Terms of Use Privacy Policy California Compliance Careers © 2020 Metuchen. All Rights Reserved.